Knoechel B, Roderick JE, Williamson KE, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364-70. doi:10.1038/ng.2913
Yuan Y, Wang Q, Paulk J, et al. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012;7(7):1152-7. doi:10.1021/cb300139y
Paez G, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-500. doi:10.1126/science.1099314
Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25(6):903-15. doi:10.1016/j.molcel.2007.03.003
Urgaonkar S, La Pierre HS, Meir I, Lund H, Raychaudhuri D, Shaw JT. Synthesis of antimicrobial natural products targeting FtsZ: (+/-)-dichamanetin and (+/-)-2’ ’’-hydroxy-5’ ’-benzylisouvarinol-B. Org Lett. 2005;7(25):5609-12. doi:10.1021/ol052269z
Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35. doi:10.1126/science.1132939
Mitchell JM, Shaw JT. Synthesis and stereochemical assignment of brasilibactin A. Org Lett. 2007;9(9):1679-81. doi:10.1021/ol070355o
Vegas AJ, Bradner JE, Tang W, et al. Fluorous-based small-molecule microarrays for the discovery of histone deacetylase inhibitors. Angew Chem Int Ed Engl. 2007;46(42):7960-4. doi:10.1002/anie.200703198
Mazitschek R, Patel V, Wirth DF, Clardy J. Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. Bioorg Med Chem Lett. 2008;18(9):2809-12. doi:10.1016/j.bmcl.2008.04.007
Hahn CK, Ross KN, Warrington IM, et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A. 2008;105(28):9751-6. doi:10.1073/pnas.0710413105